Kim J, Lee Y, Lee J, Hwang J
BMC Gastroenterol. 2025; 25(1):138.
PMID: 40045214
PMC: 11883955.
DOI: 10.1186/s12876-025-03746-w.
Zhan T, Betge J, Schulte N, Dreikhausen L, Hirth M, Li M
Signal Transduct Target Ther. 2025; 10(1):24.
PMID: 39809756
PMC: 11733248.
DOI: 10.1038/s41392-024-02097-4.
Suzuki H, Kuwano A, Takahira J, Tanaka K, Yada M, Motomura K
Cancer Diagn Progn. 2025; 5(1):132-137.
PMID: 39758246
PMC: 11696337.
DOI: 10.21873/cdp.10422.
Ursprung S, Thaiss W, Beha J, Moller Y, Malek N, Beer M
J Pers Med. 2024; 14(12).
PMID: 39728056
PMC: 11679776.
DOI: 10.3390/jpm14121143.
Chen Z, Song H, Tang J, Liu J, Xia L
Discov Oncol. 2024; 15(1):726.
PMID: 39612077
PMC: 11607260.
DOI: 10.1007/s12672-024-01628-3.
Burden and risk factors of suspected cholangiocarcinoma in high Opisthorchis viverrini endemic rural communities in southern Lao PDR.
Homsana A, Southisavath P, Kling K, Hattendorf J, Vorasane S, Paris D
PLoS Negl Trop Dis. 2024; 18(11):e0012617.
PMID: 39602377
PMC: 11602099.
DOI: 10.1371/journal.pntd.0012617.
Unveiling novel serum biomarkers in intrahepatic cholangiocarcinoma: a pilot proteomic exploration.
Mocan L, Grapa C, Craciun R, Pralea I, Uifalean A, Soporan A
Front Pharmacol. 2024; 15:1440985.
PMID: 39286634
PMC: 11403330.
DOI: 10.3389/fphar.2024.1440985.
Extrahepatic biliary neuroendocrine tumors: A national cancer database analysis.
Dominguez D, Eade A, Aversa J, Hagerty B, Blakely A, Davis J
Heliyon. 2024; 10(15):e34714.
PMID: 39144996
PMC: 11320154.
DOI: 10.1016/j.heliyon.2024.e34714.
Widening Health Disparities: Increasing Cholangiocarcinoma Incidence in an Underserved Population.
Kumar D, Bansal V, Raza S, Thrift A, Malaty H, Sealock R
Gastro Hep Adv. 2024; 1(2):180-185.
PMID: 39131132
PMC: 11308073.
DOI: 10.1016/j.gastha.2021.12.003.
Hepatic arterial infusion chemotherapy combined with toripalimab and surufatinib for the treatment of advanced intrahepatic cholangiocarcinoma.
Song S, Liu Y, Ren Y, Zheng C, Liang B
Diagn Interv Radiol. 2024; 31(2):145-151.
PMID: 38836437
PMC: 11880864.
DOI: 10.4274/dir.2024.242673.
Cholangiocarcinoma imaging: from diagnosis to response assessment.
Cao J, Srinivas-Rao S, Mroueh N, Anand R, Kongboonvijit S, Sertic M
Abdom Radiol (NY). 2024; 49(5):1699-1715.
PMID: 38578323
DOI: 10.1007/s00261-024-04267-y.
National guidelines for the diagnosis and treatment of hilar cholangiocarcinoma.
Dar F, Abbas Z, Ahmed I, Atique M, Aujla U, Azeemuddin M
World J Gastroenterol. 2024; 30(9):1018-1042.
PMID: 38577184
PMC: 10989497.
DOI: 10.3748/wjg.v30.i9.1018.
Role of long non-coding RNAs in cholangiocarcinoma: A systematic review and meta-analysis.
Shobeiri P, Bahri R, Khadembashiri M, Khadembashiri M, Maleki S, Eslami M
Cancer Rep (Hoboken). 2024; 7(3):e2029.
PMID: 38517409
PMC: 10959185.
DOI: 10.1002/cnr2.2029.
Percutaneous microwave ablation for early-stage intrahepatic cholangiocarcinoma: A single-institutional cohort.
Humphrey S, Newcomer J, Raissi D, Gabriel G
J Clin Imaging Sci. 2024; 14:4.
PMID: 38469173
PMC: 10927040.
DOI: 10.25259/JCIS_59_2023.
Nodal recurrence mapping and clinical target volumes after resection of intrahepatic cholangiocarcinoma or combined hepatocellular-cholangiocarcinoma.
Yang Z, Wang L, Zhai Y, Zhao J, Ye F, Wang S
Clin Transl Radiat Oncol. 2024; 45:100749.
PMID: 38425471
PMC: 10904232.
DOI: 10.1016/j.ctro.2024.100749.
Novel Adiponectin Receptor Agonist Inhibits Cholangiocarcinoma via Adenosine Monophosphate-activated Protein Kinase.
Bui K, Nguyen T, Barat S, Scholta T, Xing J, Bhuria V
Curr Med Chem. 2024; 31(28):4534-4548.
PMID: 38361349
DOI: 10.2174/0109298673254969231122114107.
Regulation of lipid metabolism by APOE4 in intrahepatic cholangiocarcinoma the enhancement of ABCA1 membrane expression.
Qian L, Wang G, Li B, Su H, Qin L
PeerJ. 2024; 12:e16740.
PMID: 38274331
PMC: 10809977.
DOI: 10.7717/peerj.16740.
Postpartum related intrahepatic cholangiocarcinoma with fusion and severe hyperbilirubinemia with response to FGFR inhibitor pemigatinib: case report and review.
Washburn L, Mahipal A, Jatoi A, Kottschade L, Tran N
J Gastrointest Oncol. 2024; 14(6):2627-2636.
PMID: 38196530
PMC: 10772695.
DOI: 10.21037/jgo-23-693.
ALOX5 acts as a key role in regulating the immune microenvironment in intrahepatic cholangiocarcinoma, recruiting tumor-associated macrophages through PI3K pathway.
Chen J, Tang Y, Qin D, Yu X, Tong H, Tang C
J Transl Med. 2023; 21(1):923.
PMID: 38124204
PMC: 10734103.
DOI: 10.1186/s12967-023-04804-1.
PLK1 and its substrate MISP facilitate intrahepatic cholangiocarcinoma progression by promoting lymphatic invasion and impairing E-cadherin adherens junctions.
Pan Y, Lai J, Huang W, Peng P, Jung S, Lin S
Cancer Gene Ther. 2023; 31(2):322-333.
PMID: 38057358
PMC: 10874889.
DOI: 10.1038/s41417-023-00705-z.